Cell News and Research

RSS

EHSI's NASA bioreactor will help reduce pain and trauma caused by harvesting of adult stem cells

Emerging Healthcare Solutions, Inc. expects that the company's NASA-developed bioreactor will help reduce patients' pain and trauma caused by the harvesting of adult stem cells for therapeutic and research purposes, said EHSI President and CEO Cindy Morrissey.

21 Jan 2011

NGOs, IAOMT urge to ban mercury-containing products, including dental amalgam

Mercury, the main ingredient in "silver" or amalgam fillings, will be the subject of a United Nations conference to be held in Chiba, Japan on January 24-28. Members of various non-governmental organizations, as well as dentists and scientists from groups such as the International Academy of Oral Medicine and Toxicology, will be attending and urging a ban on products containing mercury, including dental amalgam.

21 Jan 2011

NeoStem completes merger with Progenitor Cell Therapy

NeoStem, Inc. and Progenitor Cell Therapy LLC announced today the closing of their previously announced merger transaction.

21 Jan 2011

Researchers take systematic approach to catalog factors that control blood cell development

A small pool of stem cells replenishes the human body with about 200 billion new blood cells daily. But the elaborate circuitry that determines if a cell will develop into a T cell, red blood cell, or one of the nine or more other blood cell types remains largely unknown. A research team led by scientists from the Broad Institute and Brigham and Women's Hospital has taken a systematic approach to help decipher this circuitry, compiling a comprehensive catalog of the factors that determine a blood cell's fate.

21 Jan 2011

New study reports success of growing human liver cells on resorbable scaffolds

A new study reports on the success of growing human liver cells on resorbable scaffolds made from material similar to surgical sutures. Researchers suggest that this liver tissue could be used in place of donor organs during liver transplantation or during the bridge period until a suitable donor is available for patients with acute liver failure.

21 Jan 2011

OriGene releases 1,500 mouse monoclonal antibodies

OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity.

21 Jan 2011

Researchers believe driver mutations promote development, growth of prostate cancer

Prostate cancer is known to occur typically in older men. Yet some patients are younger than 50 years at the time of diagnosis. Scientists assume that these cases might be the key to understanding the biology of this disease. Early prostate cancer might be a subtype which is characterized by a relatively small number of genetic modifications.

21 Jan 2011

New research says EPO hormone can modulate immune response

New research reveals that a hormone best known for stimulating the production of red blood cells can modulate the immune response. The study, published by Cell Press in the January 27th issue of the journal Immunity, finds that erythropoietin has contrasting influences on infectious and inflammatory diseases and may be useful in the design of new therapeutic strategies.

21 Jan 2011

Scientists find ADAR1 enzyme protect against measles virus

Scientists at The Scripps Research Institute have found that a known enzyme in cells protects against measles virus, likely by altering the virus's genetic material, RNA. Cells lacking the enzyme become highly vulnerable to the virus's destructive effects. The enzyme also protects against several other respiratory viruses, including influenza A.

21 Jan 2011

Positive results from nimotuzumab Phase II study for gastric cancer

YM BioSciences, a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.

21 Jan 2011

Three ASM scientists to receive NAS award for excellence in microbiology field

Three members of the American Society for Microbiology are among the 13 scientists that will be honored by the National Academy of Sciences with awards recognizing extraordinary scientific achievement in the field of microbiology:

21 Jan 2011

University of Granada research warns about negative effects of benevolent sexism

Research conducted at the University of Granada warns about the negative effects of the so-called "benevolent sexism", a term used for apparently "positive" ideas and attitudes of men towards women, which are based on the assumption that men must take care of and sacrifice themselves for women.

21 Jan 2011

Scientists decipher genetic code for a pancreatic cancer type

Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors. The work, described online in the Jan. 20 issue of Science Express, shows that patients whose tumors have certain coding "mistakes" live twice as long as those without them.

21 Jan 2011

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.

20 Jan 2011

Alliqua completes transdermal pain patch initial study for treatment of PHN

Alliqua, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial study for the transdermal pain patch project.

20 Jan 2011

Study demonstrates prognostic value of DiagnoCure's Previstage GCC Colorectal Cancer Staging Test

DiagnoCure Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering lab services, today announced positive initial results of a multi-center clinical study of 241 stage II colon cancer patients, a population categorized as low risk by traditional methods yet with an average recurrence rate of 20%.

20 Jan 2011

FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to RiVax™ for the prevention of ricin intoxication. RiVax™ is a proprietary vaccine that contains a recombinant subunit of the A chain of ricin toxin which induces ricin neutralizing antibodies in humans and animals.

20 Jan 2011

ERC selects Elsevier's SciVerse Scopus database to track and award research funding opportunities

Elsevier's SciVerse Scopus database was selected by the European Research Council (ERC) to assist in the tracking and awarding of funding opportunities for researchers throughout the world.

20 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Cell News and Research

EHSI's NASA bioreactor will help reduce pain and trauma caused by harvesting of adult stem cells

NGOs, IAOMT urge to ban mercury-containing products, including dental amalgam

NeoStem completes merger with Progenitor Cell Therapy

Researchers take systematic approach to catalog factors that control blood cell development

New study reports success of growing human liver cells on resorbable scaffolds

OriGene releases 1,500 mouse monoclonal antibodies

Researchers believe driver mutations promote development, growth of prostate cancer

New research says EPO hormone can modulate immune response

Scientists find ADAR1 enzyme protect against measles virus

Positive results from nimotuzumab Phase II study for gastric cancer

Three ASM scientists to receive NAS award for excellence in microbiology field

University of Granada research warns about negative effects of benevolent sexism

Scientists decipher genetic code for a pancreatic cancer type

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Alliqua completes transdermal pain patch initial study for treatment of PHN

Study demonstrates prognostic value of DiagnoCure's Previstage GCC Colorectal Cancer Staging Test

FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication

ERC selects Elsevier's SciVerse Scopus database to track and award research funding opportunities

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

What are the challenges of cell line development? eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics